AC Immune SA (ACIU)
3.29
+0.05
(+1.54%)
USD |
NASDAQ |
Nov 21, 16:00
3.285
0.00 (0.00%)
Pre-Market: 20:00
AC Immune Shareholders Equity (Quarterly): 154.72M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 154.72M |
| June 30, 2024 | 137.30M |
| March 31, 2024 | 160.35M |
| December 31, 2023 | 191.25M |
| September 30, 2023 | 137.35M |
| June 30, 2023 | 154.94M |
| March 31, 2023 | 167.42M |
| December 31, 2022 | 182.27M |
| September 30, 2022 | 194.90M |
| June 30, 2022 | 212.51M |
| March 31, 2022 | 231.93M |
| December 31, 2021 | 253.78M |
| September 30, 2021 | 191.79M |
| June 30, 2021 | 205.52M |
| March 31, 2021 | 220.19M |
| December 31, 2020 | 246.63M |
| September 30, 2020 | 253.64M |
| June 30, 2020 | 263.76M |
| Date | Value |
|---|---|
| March 31, 2020 | 276.65M |
| December 31, 2019 | 281.18M |
| September 30, 2019 | 294.96M |
| June 30, 2019 | 279.77M |
| March 31, 2019 | 242.89M |
| December 31, 2018 | 180.41M |
| September 30, 2018 | 195.62M |
| June 30, 2018 | 95.61M |
| March 31, 2018 | 110.98M |
| December 31, 2017 | 119.95M |
| September 30, 2017 | 116.06M |
| June 30, 2017 | 126.51M |
| March 31, 2017 | 132.98M |
| December 31, 2016 | 139.92M |
| September 30, 2016 | 151.31M |
| June 30, 2016 | 92.42M |
| March 31, 2016 | 67.02M |
| December 31, 2015 | 71.87M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
137.30M
Minimum
Jun 2024
281.18M
Maximum
Dec 2019
205.90M
Average
200.21M
Median
Shareholders Equity (Quarterly) Benchmarks
| CRISPR Therapeutics AG | 1.940B |
| Addex Therapeutics Ltd | 14.07M |
| NLS Pharmaceutics Ltd | -9.268M |
| Molecular Partners AG | 164.96M |
| MoonLake Immunotherapeutics | 488.20M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 290.33M |
| Total Liabilities (Quarterly) | 135.61M |
| Current Ratio | 1.858 |